Myriad Genetics (MYGN) Inventory Average (2011 - 2026)

Myriad Genetics (MYGN) has 16 years of Inventory Average data on file, last reported at $29.2 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $29.2 million, up 4.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.2 million (up 4.84% YoY), and the FY2025 annual result was $29.0 million, up 17.37% from the prior year.
• Inventory Average declined to $29.2 million in Q1 2026 per MYGN's latest filing, from $31.1 million in the prior quarter.
• Over five years, Inventory Average peaked at $31.1 million in Q4 2025 and troughed at $15.4 million in Q1 2022.
• A 5-year average of $24.0 million and a median of $23.8 million in 2023 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2022 and 2023: Inventory Average plunged 40.23% in 2022, then surged 42.9% in 2023.
• A 5-year view of Inventory Average shows it stood at $19.8 million in 2022, then grew by 18.64% to $23.6 million in 2023, then grew by 14.01% to $26.8 million in 2024, then rose by 15.83% to $31.1 million in 2025, then declined by 5.95% to $29.2 million in 2026.
• Business Quant data shows MYGN's Inventory Average at $29.2 million in Q1 2026, $31.1 million in Q4 2025, and $30.2 million in Q3 2025.